2018
DOI: 10.1210/er.2018-00168
|View full text |Cite
|
Sign up to set email alerts
|

Gastrointestinal Malabsorption of Thyroxine

Abstract: at the modification stage), and do not reflect editorial changes. No corrections/changes to the PDF manuscripts are accepted. Accordingly, there likely will be differences between the Advance Article manuscripts and the final, typeset articles. The manuscripts remain listed on the Advance Article page until the final, typeset articles are posted. At that point, the manuscripts are removed from the Advance Article page. DISCLAIMER: These manuscripts are provided "as is" without warranty of any kind, either expr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

5
168
0
4

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 118 publications
(177 citation statements)
references
References 239 publications
(308 reference statements)
5
168
0
4
Order By: Relevance
“…Moreover, no recommendations are reported by other specialized societies about the indications for the use of these novel LT4 formulations [14][15][16]. Giving the high level of evidence on the efficacy and safety of LT4 LS/SG formulations [9,12,13] subsequent to these guidelines [1,[14][15][16] and considering the worldwide prevalence of gastrointestinal disorders that considerably impact on LT4 tablet absorption [17,18], the indications of LT4 nontablet formulations should be reappraised.…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, no recommendations are reported by other specialized societies about the indications for the use of these novel LT4 formulations [14][15][16]. Giving the high level of evidence on the efficacy and safety of LT4 LS/SG formulations [9,12,13] subsequent to these guidelines [1,[14][15][16] and considering the worldwide prevalence of gastrointestinal disorders that considerably impact on LT4 tablet absorption [17,18], the indications of LT4 nontablet formulations should be reappraised.…”
Section: Discussionmentioning
confidence: 99%
“…Nonadherence to medications is a major challenge in the management of thyroxine treatment. When patients do not take L‐T4 regularly or do not comply with timing in relation to food ingestion and fail to report such behaviours to the endocrinologist, the clinician may wonder about the cause of a persistently elevated TSH, despite a high L‐T4 dose . Guidelines suggest that L‐T4 should be taken well before 1 hour of eating breakfast.…”
Section: Discussionmentioning
confidence: 99%
“…5 The small bowel is the principal site of levothyroxine absorption by a process of translocation across the mucosa that remains uncertain. [6][7][8] There is a prolonged exposure of the levothyroxine to the intestinal wall due to slow bowel motility at night, resulting in improved uptake. When greater than regular dose is required to maintain TSH in the normal range in post total thyroidectomy patients, it's vital for the surgeon to find out the reason behind it.…”
Section: Discussionmentioning
confidence: 99%